← Leaderboards
R. Sharon Chinthrajah
Stanford University
$3,711,935
Attributed
$4,091,935
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $733.1K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,091,935 · 5
By mechanism
U19$1,686,935 · 3
UM1$1,645,000 · 1
U01$760,000 · 1
Top collaborators
- Sayantani B. Sindher2 shared
Most similar at Stanford University
Same institution · by research overlap
- Kari C. Nadeau$30,132,783
- Bali Pulendran$71,035,530
- Scott Dexter Boyd$18,651,021
- Paul Joseph Utz$20,350,048
- Mark M Davis$39,722,191
Others in their field
Other Emerging Leaders on “Participant”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$102,389,765
- Scott Topper · Broad Institute, Inc.$101,052,360
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
Research focus
ParticipantSuccessImmune ResponseFood HypersensitivitySafetyProtocols DocumentationFood ChallengeSiteFood AllergenOral ImmunotherapyBasophilsAllergensAllergicRegimenFoodDesensitizationBloodSamplingClinical ResearchData SetLaboratoriesScreeningImmunotherapyRandomized
Grant awards (17)
Therapeutic and Mechanistic Insights in Food Allergy$380,000
U01 · FY2025 · AI
Clinical Core$256,393
U19 · FY2025 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$96,737
U19 · FY2025 · AI · contact PI
Therapeutic and Mechanistic Insights in Food Allergy$380,000
U01 · FY2024 · AI
Clinical Core$312,716
U19 · FY2024 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$299,206
U19 · FY2023 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2023 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2022 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$161,924
U19 · FY2022 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2021 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$188,254
U19 · FY2021 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2020 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$188,257
U19 · FY2020 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2019 · AI · contact PI
A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals$183,448
U19 · FY2019 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2018 · AI · contact PI
Evaluating the role of allergen dose and duration in the safety and efficacy of multi-allergen oral immunotherapy with Omalizumab$235,000
UM1 · FY2017 · AI · contact PI